Antiphospholipid syndrome (APS) is an autoimmune thrombophilia propelled by circulating
antiphospholipid antibodies that herald vascular thrombosis and obstetrical complications …

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

Objective Antiphospholipid antibodies (aPL), especially those targeting β2‐glycoprotein I
(β2GPI), are well known to activate endothelial cells, monocytes, and platelets, with …

First described in the early 1980s, antiphospholipid syndrome (APS) is a unique form of
acquired autoimmune thrombophilia in which patients present with clinical features of …

Objective Antiphospholipid syndrome (APS) is a leading acquired cause of thrombotic
events. Although antiphospholipid antibodies have been shown to promote thrombosis in …

Objective An international multidisciplinary initiative, jointly supported by the American
College of Rheumatology and European Alliance of Associations for Rheumatology, is …

The purpose of this task force was to critically analyze nine non-criteria manifestations of
APS to support their inclusion as APS classification criteria. The Task Force Members …

Abstract Beta-2-Glycoprotein I (β2GPI) plays a number of essential roles throughout the
body. β2GPI, C-reactive protein and thrombomodulin are the only three proteins that …

Extracellular chromatin, for example in the form of neutrophil extracellular traps (NETs), is an
important element that propels the pathological progression of a plethora of diseases. DNA …

Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report
the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or …